66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 255 / Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05125068 (ClinicalTrials.gov) | February 28, 2022 | 8/11/2021 | Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) | A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy | IgA Nephropathy;IgAN | Drug: AT-1501 | Eledon Pharmaceuticals | NULL | Not yet recruiting | 18 Years | 99 Years | All | 42 | Phase 2 | NULL |